Julphar Shareholders Approve Financing Plan To Wipe Out Losses
Losses To Be Extinguished, Capital Increased
Julphar has suffered an alarming turn in fortune in the last two years, on the back of export bans that have severed access to some of the company’s key markets in the Middle East. With a new CEO in place, the company is looking to transform its fortunes this year, aided by a capital restructuring that just been greenlit by shareholders.
You may also be interested in...
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.
As its CEO Jerome Carle steps down following a 67% slump in sales to date this year, UAE-based Julphar is hopeful of putting manufacturing problems behind it under a new management team.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.